Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. - Wikidata - awgldk - TriplyDB

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.

http://www.wikidata.org/entity/Q35638631

about

Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies Clinical outcomes in psoriatic arthritis: A systematic literature review Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis.Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies.Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis.HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab.Adalimumab in dermatology The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people.Drug focus: adalimumab in the treatment of moderate to severe psoriasis.Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature.Long-term use of adalimumab in the treatment of rheumatic diseases.The efficacy and safety of golimumab in the treatment of arthritis.The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities.Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis.Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Application of the dermatology life quality index in clinical trials of biologics for psoriasis.Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Chec Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.Diagnosing and treating psoriatic arthritis: an update.Biomarkers and immunomodulation as a treatment option for chronic pain conditions.Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety.Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity.Certolizumab pegol for the treatment of psoriatic arthritis.Update in treatment options for psoriatic arthritis.Leflunomide in psoriatic arthritis: results from a large European prospective observational study.Effects of adalimumab therapy on musculoskeletal manifestations and health-related quality of life in patients with active psoriatic arthritis.Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial.Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients.Altered Bone Remodeling in Psoriatic Disease: New Insights and Future Directions.Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.Adalimumab for the treatment of psoriatic arthritis.Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

P2860

Q26764867-3413325C-947F-491D-AB9B-9E4D44BC65EE Q26995307-85EFBDF8-CA70-4EC0-B857-8D6E34259EB1 Q31169591-169BD1F0-1815-471C-93C0-9AD5B8D6D35E Q33673930-E652CD74-2E40-4F5E-8FB1-36D8F30FD842 Q34017619-A999675E-36F5-4E55-BF97-2DE746E9903B Q34228353-05CB9E67-FDC4-4D5B-9BEA-654B2A0F0D3C Q36479450-AC0A08B2-4597-419B-972B-6859AB990A54 Q36759489-70E3EF12-43D5-4D3D-80D2-2E9B62897D04 Q37142425-A3760701-2065-4541-B4E4-139A14F212DF Q37172521-99B2E553-31F5-4CA8-990C-A6B75EAFAD9D Q37290478-EDEB60E5-206E-4ACC-9415-E728CF0E5C20 Q37303223-EB6445B3-F451-4F2F-AA35-9190D33D62DB Q37358124-F4553A6E-D71E-4755-8063-4AF7C9E7FBF1 Q37760938-79A943BB-FC4B-4900-9CC7-93625969209A Q37766229-470D9AA8-4295-4C3E-8BDC-64D841105008 Q37826195-834E2697-193F-4166-BBD7-7456A7C19677 Q37873493-FA2F795E-46BF-4212-852E-A283629E0B5F Q37998917-FC791EE8-27B6-40C3-AEF9-424E04BF2ECD Q38010362-E9CAD013-8CD8-4200-A81E-72F594ECE229 Q38099408-4661BCE0-4CA9-4A6F-9332-4151E2CA450B Q38165235-9CC77627-1195-4A60-AD63-2A010458BD1D Q38198083-149BFC3E-725D-413D-BA38-D38B604DBDFC Q38204241-5D3E1200-3A17-4C48-A5A0-68B91F09B435 Q38264660-B1EED943-0223-4CDE-A611-5C5974919F28 Q38344194-71F46A57-1951-4301-BBB3-85B96BA15077 Q43061552-8254B1C2-B863-4AC6-88FB-B49E6AA742D0 Q43673954-35F922B6-A2F9-4EA3-BF07-F10BA8C3382E Q44450869-D50DC6FB-1708-455F-B75F-D2BC222AEA39 Q46625937-16DDD4EB-2AB5-43EC-B85A-26AC0AC8888B Q46958700-6F5DAF0C-008E-4436-BE10-07627016DE33 Q47734526-1CD25AB7-3DEA-4213-B795-A730125B5B00 Q48559584-F5EF57C9-7EFD-416B-9A6F-82E1E616F4EB Q52903765-EC6C338C-3351-4BEC-B454-084B30301B18 Q54978927-A7E366F5-5788-4621-A9E5-CF060E867577

P2860

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.

http://www.wikidata.org/entity/Q35638631

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Adalimumab improves joint-rela ...... in Psoriatic Arthritis Trial.

@ast

Adalimumab improves joint-rela ...... in Psoriatic Arthritis Trial.

@en

type

label

Adalimumab improves joint-rela ...... in Psoriatic Arthritis Trial.

@ast

Adalimumab improves joint-rela ...... in Psoriatic Arthritis Trial.

@en

prefLabel

Adalimumab improves joint-rela ...... in Psoriatic Arthritis Trial.

@ast

Adalimumab improves joint-rela ...... in Psoriatic Arthritis Trial.

@en

P1433

Q35638631-0F94002D-EA6A-4175-AFC1-64B1E414F370

P1476

Q35638631-13038FBD-A804-4B5E-927C-971364973324

P2093

Q35638631-111CBD06-68C7-42C7-A657-A7FBD7E9AF7B

Q35638631-A6882949-27B8-4A54-A790-089817C9591E

Q35638631-A6BCA6D2-751F-4F11-B8AA-03FEB1170D6C

Q35638631-D76C1D5F-2227-4CBC-BA52-9941BEE86621

Q35638631-F5A19629-8C80-454E-8C9A-BBA377CADF2D

P2860

Q35638631-260F5043-7F94-4F7C-A828-5A050734DA2C

Q35638631-26B39671-8976-4472-B7FF-A4E46BD57AF6

Q35638631-492A8442-BE3C-4470-9F76-598476A105DE

Q35638631-5BE8919F-FAC8-4D13-9AA6-F5192C0D57BA

Q35638631-5DB4B848-C263-438C-BB26-F0A59BE7F8CD

Q35638631-67890434-2BB3-4131-8CDB-AB04FBA3D572

Q35638631-6CAF6038-E488-4B71-BF21-327A434815AF

Q35638631-6CF4AE03-7CBF-44E6-A4D7-E70248DA7BD1

Q35638631-788E84ED-2774-448A-BD3C-BFE0340B3CAE

Q35638631-88F1DCCB-4EE7-4736-8592-D78BD9C9946F

P304

Q35638631-17ABC123-CB6F-45C0-8BC7-54DD5EE70590

P31

Q35638631-45FA0C2A-C7B8-47B6-A807-337E2CFDE715

P356

Q35638631-C624CB53-D9AD-483C-8D93-03180BD857A8

P407

Q35638631-1E174B1A-EBC1-479D-A6F9-FEBA3A53B1A2

P433

Q35638631-9DEF9679-28D6-4461-8DD8-051610C1E99B

P478

Q35638631-80201303-8028-4FA8-949D-0E8B2FC3D47A

P50

Q35638631-AA4BD7AE-118D-4775-A64A-2C60309B854A

P577

Q35638631-8069643F-1FCC-4ABD-AF0C-AE51123A9419

P5875

Q35638631-387EFE99-12F9-4BE8-B1CF-5ACDF622BA14

P698

Q35638631-A6B2B296-1486-4D14-BDFD-AE65BBD5BEFC

P921

Q35638631-41775B55-4642-409E-8B4A-8E5428FEA151

Q35638631-9D397A91-8A3A-4790-9DAF-FFA853E4F43A

P932

Q35638631-B5F60A06-BC3D-478B-9A78-213A809A298B

P356

ARD.2006.057901

P1433

Annals of the Rheumatic Diseases

P1476

Adalimumab improves joint-rela ...... in Psoriatic Arthritis Trial.

@en

P2093

E Sasso

http://www.w3.org/2001/XMLSchema#string

J Medich

http://www.w3.org/2001/XMLSchema#string

M A Cifaldi

http://www.w3.org/2001/XMLSchema#string

P J Mease

http://www.w3.org/2001/XMLSchema#string

R J Perdok

http://www.w3.org/2001/XMLSchema#string

P2860

The MOS 36-ltem Short-Form Health Survey (SF-36)

Dermatology life quality index: data from Danish inpatients and outpatients.

Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study.

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.

Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors

Psoriasis treatment: current and emerging directed therapies.

Psoriatic arthritis: epidemiology, clinical features, course, and outcome.

Psoriatic arthritis assessment tools in clinical trials.

Use of the Dermatology Life Quality Index (DLQI) in a midwestern US urban clinic.

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

P304

163-168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2006.057901

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

Dafna D. Gladman

P577

2006-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6748593

http://www.w3.org/2001/XMLSchema#string

P698

17046964

http://www.w3.org/2001/XMLSchema#string

P921

P932

1798491

http://www.w3.org/2001/XMLSchema#string